Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA denies breakthrough for Ariad's AP26113

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) disclosed on a conference call to discuss its 2Q13 earnings on Wednesday that FDA denied breakthrough therapy designation for the company's AP26113 for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE